Verbatim response from ChatGPT
Short version
- The FDA has cracked down on pharmacies that were compounding copy‑cat GLP‑1 products (semaglutide, tirzepatide, etc.) from bulk peptide ingredients. The agency says most of those compounds are not legal to make or distribute because they are essentially unapproved copies of FDA‑approved biologics and/or are being made from bulk drug substances that FDA hasn’t authorized for compounding.
- FDA enforcement has included public safety communications and warning letters to compounding firms; the result is many compounding operations stopped, changed what they offer, or are under FDA/state inspection.
- Legally operating options now are: (a) obtaining FDA‑approved GLP‑1 drugs through licensed prescribers and legitimate pharmacies; (b) compounding only in narrow, lawful ways (patient‑specific 503A compounding that meets state/FDA rules) or by FDA‑registered 503B outsourcing facilities that comply with CGMP and applicable restrictions.
More detail
What the FDA said and did
- FDA’s position: compounding pharmacies should not make unapproved, stand‑alone copies of FDA‑approved GLP‑1 biologics by using bulk active pharmaceutical ingredients (APIs) sourced from foreign suppliers. The agency emphasizes risks (contamination, incorrect strength, sterility problems) and that compounding from bulk peptide APIs is heavily restricted.
- Actions: FDA issued warning letters and public advisories to compounding pharmacies and clinics; asked some firms to stop making or distributing compounded GLP‑1 products; and reminded prescribers, pharmacies and states of the legal limits on compounding. (For the latest enforcement actions and exact letters, see the FDA website under “compounding” and “GLP‑1” announcements.)
Who can still operate legally
- FDA‑approved manufacturers and normal pharmacies: Manufacturers of FDA‑approved GLP‑1 drugs (for example Novo Nordisk — Ozempic, Wegovy; Eli Lilly — Mounjaro, Zepbound) and licensed retail/specialty pharmacies that dispense those FDA‑approved products are fully legal and the safest option.
- 503A compounding pharmacies: These can legally compound medications only on the basis of a valid prescription for an individually identified patient, and they must follow state law and FDA guidance. They generally cannot make copies of an FDA‑approved drug or routinely compound from bulk APIs that aren’t on FDA’s allowed lists.
- 503B outsourcing facilities: These are FDA‑registered facilities that can compound without individual patient prescriptions but must meet current good manufacturing practices (CGMP). They are subject to direct FDA oversight; they may still compound certain items if they comply with FDA restrictions and do not make prohibited copies of approved products.
How this affects consumers and what to do
- Safer route: If you need a GLP‑1, ask your clinician to prescribe an FDA‑approved product (Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, etc.) and have it filled at a reputable pharmacy—major retail or specialty pharmacies (for example, CVS Specialty, Accredo, Optum/Diplomat, AllianceRx Walgreens Prime) handle specialty biologics and proper storage/handling.
- If a prescriber or clinic offers a compounded GLP‑1, ask for:
- A valid, patient‑specific prescription.
- The pharmacy’s state license and accreditation (USP <797> compliance, PCAB/NABP or other recognized compounding accreditation where applicable).
- Certificate of analysis (COA) and sterility/quality testing results for the batch.
- Evidence the pharmacy is operating under 503A rules or is an FDA‑registered 503B facility.
- Check sources: verify any specific pharmacy or clinic with your state Board of Pharmacy and consult the FDA’s compounding and enforcement pages for current guidance.
If you want, I can:
- Look up the current FDA enforcement notices (if you give me a specific pharmacy or clinic name), or
- Help you find nearby pharmacies or specialty pharmacies that routinely dispense FDA‑approved GLP‑1 medications.